Actelion Pharmaceuticals Ltd : CEPTARIS RECEIVES US FDA APPROVAL FOR VALCHLOR - A SIGNIFICANT CLOSING CONDITION OF ACTELION'S

Actelion Pharmaceuticals Ltd : CEPTARIS RECEIVES US FDA APPROVAL FOR VALCHLOR
- A SIGNIFICANT CLOSING CONDITION OF ACTELION'S ACQUISITION OF PRIVATELY-HELD
                                   CEPTARIS

Actelion Pharmaceuticals Ltd / CEPTARIS RECEIVES US FDA APPROVAL FOR VALCHLOR
- A SIGNIFICANT CLOSING CONDITION OF ACTELION'S ACQUISITION OF PRIVATELY-HELD
CEPTARIS . Processed and transmitted by Thomson Reuters ONE. The issuer is
solely responsible for the content of this announcement.

ALLSCHWIL / BASEL, SWITZERLAND - 26  August 2013 - Actelion (SIX: ATLN)  today 
highlighted the announcement  from Ceptaris Therapeutics,  Inc., which  stated 
that the US Food and Drug Administration (FDA) has granted marketing  approval 
for VALCHLOR(TM) (mechlorethamine)  Gel 0.016%  for the  topical treatment  of 
stage IA and  IB mycosis  fungoides-type cutaneous T-cell  lymphoma (CTCL)  in 
patients who have received prior skin directed therapy.

On July 30, 2013  Actelion US Holding Company,  a subsidiary of Actelion  Ltd, 
and Ceptaris Therapeutics,  Inc. entered  into an  agreement whereby  Actelion 
would acquire  Ceptaris. Under  the  terms of  the  agreement, the  merger  is 
contingent upon certain  closing conditions,  including the  announced US  FDA 
approval of Ceptaris' product, VALCHLOR.

The companies  are  now  completing  further  closing  conditions  before  the 
acquisition is concluded. Actelion will provide a further update upon closing.

The full Ceptaris statement can be found on the corporate website of Ceptaris:
http://www.ceptaris.com/news/

                                    # # #

NOTES TO THE EDITOR

ABOUT THE MERGER AGREEMENT

Actelion US  Holding  Company, a  subsidiary  of Actelion  Ltd,  and  Ceptaris 
Therapeutics, Inc. have  entered into  an agreement  whereby Actelion  acquire 
Ceptaris. Under the  terms of  the agreement,  the merger  is contingent  upon 
certain closing  conditions,  including  the  announced  US  FDA  approval  of 
Ceptaris' product, VALCHLOR.

Actelion paid  to  Ceptaris  USD 25  million  upon  signing and  will  pay  to 
Ceptaris' shareholders  USD  225  million upon  closing  of  the  transaction. 
Ceptaris' shareholders are also eligible to receive additional payments  based 
on net  sales  of  VALCHLOR  and/or  the  achievement  of  certain  commercial 
milestones.

ABOUT MYCOSIS FUNGOIDES AND CUTANEOUS T-CELL LYMPHOMA

Mycosis fungoides is the most common type of Cutaneous T-Cell Lymphoma (CTCL),
a rare form of non-Hodgkin's lymphoma. The cause of mycosis fungoides  remains 
unknown and  there is  no  known cure.  Unlike most  non-Hodgkin's  lymphomas, 
mycosis fungoides is caused by a mutation of T-cells. The malignant T-cells in
the body initially migrate to the skin, causing various lesions to appear.

These lesions typically begin as what appears to be a rash and may progress to
form plaques and disfiguring  tumors. Early stage cases  may be confused  with 
other skin conditions  until a definitive  diagnosis is made  based upon  skin 
biopsy. Most cases of mycosis fungoides  are early-stage and are diagnosed  in 
patients over the age of 50.

ABOUT MECHLORETHAMINE GEL

Mechlorethamine  is   a  chemotherapeutic   agent  previously   approved   for 
intravenous treatment of mycosis fungoides, the most common type of  Cutaneous 
T-Cell Lymphoma  (CTCL). Topical  mechlorethamine preparations  are  currently 
recommended  for  the  treatment   of  early  stage   CTCL  by  the   National 
Comprehensive Cancer  Network  (NCCN). VALCHLOR  Gel  is the  first  and  only 
FDA-approved topical formulation of mechlorethamine.

The most common  side effects associated  with VALCHLOR in  the pivotal  trial 
were  local  skin  reactions,  including  dermatitis  (56%),  pruritus  (20%), 
bacterial skin infections (11%), skin  ulceration or blistering (6%) and  skin 
hyperpigmentation (5%). The most common  of these skin reactions,  dermatitis, 
ranged from  mild to  severe. No  systemic absorption  of mechlorethamine  was 
detected with VALCHLOR treatment.

ABOUT CEPTARIS

Ceptaris Therapeutics  Inc.  is  a privately  held,  specialty  pharmaceutical 
company that  was established  to  develop a  proprietary gel  formulation  of 
mechlorethamine for  the  treatment  of early  stage  (stages  I-IIA)  mycosis 
fungoides, a type of CTCL. Ceptaris'  drug is the first FDA-approved  topical 
mechlorethamine product available to treat the signs and symptoms of this rare
cancer. Please visit http://www.ceptaris.com for more information. Ceptaris is
a NeXeption portfolio company.

ABOUT ACTELION LTD

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first  drug Tracleer® (bosentan),  an 
orally available dual endothelin receptor  antagonist, has been approved as  a 
therapy for pulmonary arterial hypertension. Actelion markets Tracleer through
its own subsidiaries  in key  markets worldwide, including  the United  States 
(based in South San Francisco),  the European Union, Japan, Canada,  Australia 
and Switzerland.  Actelion, founded  in  late 1997,  is  a leading  player  in 
innovative science related  to the  endothelium -  the single  layer of  cells 
separating every blood  vessel from  the blood stream.  Actelion's over  2,300 
employees focus  on the  discovery, development  and marketing  of  innovative 
drugs for significant unmet medical needs.  Actelion shares are traded on  the 
SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip  index 
SMI (Swiss Market Index SMI®).

For further information please contact:

Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com

The above information contains certain "forward-looking statements",  relating 
to  the  company's  business,   which  can  be  identified   by  the  use   of 
forward-looking  terminology  such  as  "estimates",  "believes",  "expects", 
"may", "are  expected  to", "will",  "will  continue", "should",  "would  be", 
"seeks", "pending" or "anticipates" or similar expressions, or by discussions
of strategy, plans or intentions. Such statements include descriptions of the
company's investment  and research  and development  programs and  anticipated 
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect  the 
current views of the company with respect to future events and are subject  to 
certain risks, uncertainties  and assumptions.  Many factors  could cause  the 
actual results, performance or  achievements of the  company to be  materially 
different from any future  results, performances or  achievements that may  be 
expressed or implied by such forward-looking statements. Should one or more of
these risks  or uncertainties  materialize, or  should underlying  assumptions 
prove incorrect,  actual  results may  vary  materially from  those  described 
herein as anticipated, believed, estimated or expected.

Press Release PDF

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
HUG#1724720

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;
 
Press spacebar to pause and continue. Press esc to stop.